Patient, Physician, and Payment Predictors of Statin Adherence
- 1 March 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medical Care
- Vol. 48 (3), 196-202
- https://doi.org/10.1097/mlr.0b013e3181c132ad
Abstract
Background: Although many patient, physician, and payment predictors of adherence have been described, knowledge of their relative strength and overall ability to explain adherence is limited. Objectives: To measure the contributions of patient, physician, and payment predictors in explaining adherence to statins. Research Design: Retrospective cohort study using administrative data. Subjects: A total of 14,257 patients insured by Horizon Blue Cross Blue Shield of New Jersey who were newly prescribed a statin cholesterol-lowering medication. Measures: Adherence to statin medication was measured during the year after the initial prescription, based on proportion of days covered. The impact of patient, physician, and payment predictors of adherence were evaluated using multivariate logistic regression. The explanatory power of these models was evaluated with C statistics, a measure of the goodness of fit. Results: Overall, 36.4% of patients were fully adherent. Older patient age, male gender, lower neighborhood percent black composition, higher median income, and fewer number of emergency department visits were significant patient predictors of adherence. Having a statin prescribed by a cardiologist, a patient's primary care physician, or a US medical graduate were significant physician predictors of adherence. Lower copayments also predicted adherence. All of our models had low explanatory power. Multivariate models including patient covariates only had greater explanatory power (C = 0.613) than models with physician variables only (C = 0.566) or copayments only (C = 0.543). A fully specified model had only slightly more explanatory power (C = 0.633) than the model with patient characteristics alone. Conclusions: Despite relatively comprehensive claims data on patients, physicians, and out-of-pocket costs, our overall ability to explain adherence remains poor. Administrative data likely do not capture many complex mechanisms underlying adherence.Keywords
This publication has 27 references indexed in Scilit:
- Trends in adherence to secondary prevention medications in elderly post‐myocardial infarction patientsPharmacoepidemiology and Drug Safety, 2008
- The Implications of ChoiceArchives of Internal Medicine, 2006
- Adherence to MedicationThe New England Journal of Medicine, 2005
- Long-term Persistence in Use of Statin Therapy in Elderly PatientsJama-Journal Of The American Medical Association, 2002
- Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary SyndromesJama-Journal Of The American Medical Association, 2002
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsThe New England Journal of Medicine, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJama-Journal Of The American Medical Association, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsThe New England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaThe New England Journal of Medicine, 1995
- Discontinuation of Antihyperlipidemic Drugs — Do Rates Reported in Clinical Trials Reflect Rates in Primary Care Settings?The New England Journal of Medicine, 1995